Christopher F. Wyatt, the SVP & Controller of $HCA, sold 4,000 shares of the company on 02-11-2026 for an estimated $2,020,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 8.3% of their shares of this class of stock. Following this trade, they now own 44,379 shares of this class of $HCA stock.
$HCA Insider Trading Activity
$HCA insiders have traded $HCA stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $HCA stock by insiders over the last 6 months:
- SAMUEL N HAZEN (CEO) has made 0 purchases and 7 sales selling 42,877 shares for an estimated $21,483,274.
- JENNIFER BERRES (SVP & Chief Human Res. Officer) has made 0 purchases and 2 sales selling 8,020 shares for an estimated $4,126,950.
- MICHAEL S. CUFFE (EVP and Chief Clinical Officer) has made 0 purchases and 2 sales selling 5,336 shares for an estimated $2,353,805.
- CHRISTOPHER F. WYATT (SVP & Controller) sold 4,000 shares for an estimated $2,020,000
- MICHAEL R MCALEVEY (EVP & Chief Legal & Admin Off.) sold 3,892 shares for an estimated $1,843,990
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$HCA Hedge Fund Activity
We have seen 583 institutional investors add shares of $HCA stock to their portfolio, and 652 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,465,455 shares (+74.5%) to their portfolio in Q3 2025, for an estimated $624,576,921
- LONGVIEW PARTNERS (GUERNSEY) LTD removed 1,287,869 shares (-82.4%) from their portfolio in Q3 2025, for an estimated $548,889,767
- PACER ADVISORS, INC. removed 911,096 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $425,354,278
- PRICE T ROWE ASSOCIATES INC /MD/ removed 813,787 shares (-59.6%) from their portfolio in Q3 2025, for an estimated $346,836,019
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 649,058 shares (+4545.5%) to their portfolio in Q4 2025, for an estimated $303,019,217
- JPMORGAN CHASE & CO removed 627,849 shares (-21.0%) from their portfolio in Q4 2025, for an estimated $293,117,584
- DIAMOND HILL CAPITAL MANAGEMENT INC removed 618,170 shares (-92.9%) from their portfolio in Q4 2025, for an estimated $288,598,846
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$HCA Revenue
$HCA had revenues of $19.5B in Q4 2025. This is an increase of 6.72% from the same period in the prior year.
You can track HCA financials on Quiver Quantitative's HCA stock page.
$HCA Congressional Stock Trading
Members of Congress have traded $HCA stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $HCA stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 08/19 and 1 sale worth up to $15,000 on 09/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$HCA Analyst Ratings
Wall Street analysts have issued reports on $HCA in the last several months. We have seen 13 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 01/28/2026
- Truist Securities issued a "Buy" rating on 01/28/2026
- Deutsche Bank issued a "Buy" rating on 01/28/2026
- Barclays issued a "Overweight" rating on 01/28/2026
- Jefferies issued a "Buy" rating on 01/28/2026
- Morgan Stanley issued a "Underweight" rating on 12/15/2025
- TD Cowen issued a "Buy" rating on 10/27/2025
To track analyst ratings and price targets for $HCA, check out Quiver Quantitative's $HCA forecast page.
$HCA Price Targets
Multiple analysts have issued price targets for $HCA recently. We have seen 17 analysts offer price targets for $HCA in the last 6 months, with a median target of $546.0.
Here are some recent targets:
- David Toung from Argus Research set a target price of $560.0 on 02/06/2026
- Stephen Baxter from Wells Fargo set a target price of $481.0 on 01/30/2026
- Brian Tanquilut from Jefferies set a target price of $590.0 on 01/28/2026
- Matthew Gillmor from Keybanc set a target price of $550.0 on 01/28/2026
- Pito Chickering from Deutsche Bank set a target price of $558.0 on 01/28/2026
- David Macdonald from Truist Securities set a target price of $546.0 on 01/28/2026
- Michael Wiederhorn from Oppenheimer set a target price of $540.0 on 01/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
